Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling

Imatinib was the first targeted tyrosine kinase inhibitor to be approved for clinical use, and remains first-line therapy for Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia. We show that treatment of human glioblastoma multiforme (GBM) tumour cells with imatinib and the closely...

Descripción completa

Detalles Bibliográficos
Autores principales: Frolov, Antonina, Evans, Ian M., Li, Ningning, Sidlauskas, Kastytis, Paliashvili, Ketevan, Lockwood, Nicola, Barrett, Angela, Brandner, Sebastian, Zachary, Ian C., Frankel, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904410/
https://www.ncbi.nlm.nih.gov/pubmed/27293031
http://dx.doi.org/10.1038/srep27378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904410/
https://www.ncbi.nlm.nih.gov/pubmed/27293031
http://dx.doi.org/10.1038/srep27378

Ejemplares similares